These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Characterization of Protease-Activated Receptor (PAR) Ligands: Parmodulins Are Reversible Allosteric Inhibitors of PAR1-Driven Calcium Mobilization in Endothelial Cells

submitted on 21.02.2018, 02:41 and posted on 21.02.2018, 15:36 by Disha M. Gandhi, Mark W. Majewski, Ricardo Rosas, Jr., Kaitlin Kentala, Trevor J. Foster, Eric Greve, Chris Dockendorff
We report a detailed protocol for an intracellular calcium mobilization assay with adherent endothelial cells in multiwell plates that was used to study a number of different PAR1 and PAR2 ligands, including an alkynylated version of the PAR1 antagonist RWJ-58259 that is suitable for the preparation of tagged or conjugate compounds. Using the cell line EA.hy926, it was necessary to perform media exchanges with automated liquid handling equipment in order to obtain optimal and reproducible antagonist concentration-response curves. The assay was used to confirm that vorapaxar acts as an irreversible antagonist of PAR1 in endothelium, and parmodulin 2 (ML161) and the related parmodulin RR-90 were found to inhibit PAR1 reversibly, in a manner consistent with negative allosteric modulation. Detailed synthetic protocols are also provided for several known and novel PAR ligands.


NIH R15HL127636


Email Address of Submitting Author


Marquette University



ORCID For Submitting Author


Declaration of Conflict of Interest

C.D. is co-inventor of a patent describing compounds in this manuscript (WO 2012/040636; US 9,422,262).